Novo Nordisk Shares Pop After Stepping Back From Metsera Chase

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...

Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle

Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more ...
PharmExec

Novo Nordisk Not Planning Increased Proposal Offer After Metsera Enters $10 Billion Amended Merger Agreement with Pfizer

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Novo Nordisk gives up battle for Metsera as Pfizer inks $10B deal

Pfizer (PFE) wins Metsera (MTSR) buyout after a heated bidding war with Novo Nordisk (NVO), securing a $10B deal for the ...
BioSpace

UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk Has Downgraded Its Outlook for the Fourth Time This Year. Here's What Investors Need to Know.

Big Danish drugmaker Novo Nordisk (NVO 3.88%) reported its third-quarter results on Wednesday, Nov. 5. Although sales and earnings grew year over year, the company downgraded its ...

Novo Nordisk trims outlook as obesity drug maker loses ground to Eli Lilly

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its ...